Alphatec Holdings (ATEC) reported third-quarter non-GAAP earnings of $0.09 per share. That matched the $0.09 Earnings Whisper number but fell short of the $0.11 consensus, so the earnings result looks better against the whisper than against the Street. Earnings grew 280.0% year over year. Revenue of $221.17 million rose 12.6% but missed consensus by 1.4%. The company also lowered full-year guidance for revenue, adjusted EBITDA and free cash flow. That is the central tension. Surgeon adoption and procedure volume have rarely looked better, yet less revenue is reaching the top line per procedure. CEO Pat Miles opened by acknowledging that revenue 'fell short of our expectations.'

The profitability progress is real. GAAP results swung to an operating profit of $3.2 million from a $15.9 million operating loss a year ago. The GAAP net loss narrowed to $5.5 million, or $0.03 per share, from $28.6 million, or $0.19. Non-GAAP gross margin improved to 71.9% from 70.1%. Adjusted EBITDA of $38 million rose from $26 million, lifting the margin 400 basis points to 17.3%. Free cash flow was about $6 million. However, the quality of the margin gain deserves scrutiny. Part of the gross-margin lift came from mix, as lower-margin biologics and EOS contributed less. Margin gains driven by weakness in other product lines are not the same as structural leverage, and the call flagged that they may not persist.

The underlying revenue trend is decelerating. Total growth slowed to 13% from 15% in the second quarter and 14% in the first. Surgical growth fell to 14% after two quarters at 17%. Volume was not the problem: procedures grew about 20%, hardware grew 17%, and net new surgeon users rose about 25%, up from 24% and 23% in the prior two quarters. The shortfall came from revenue per case, which fell 5% year over year after a 2.7% decline in the second quarter. Biologics revenue declined roughly $1 million year over year. Historically, biologics added $15 million to $25 million of annual growth, and management had described the business as 'stabilized' only a quarter earlier. Management also lowered its view of the spine market to low single-digit growth from mid-single digits, citing softer thoracolumbar volumes among tenured customers. Last quarter, it had pointed to 'robust volumes.' The tone shifted from 'more enthusiasm than ever' to 'clearly a frustrating quarter.'

The guidance cuts were broad. Revenue guidance fell to about $862 million from $882 million, and from $890 million at the start of the year. Surgical guidance, held for three calls, fell to $789 million from $805 million. EOS guidance was cut again, to $73 million from $77 million, against an original $85 million. Adjusted EBITDA guidance slipped to $137 million from $140 million. Free cash flow guidance was halved to about $10 million from 'at least $20 million.' Management also cited a roughly $3 million international impact from a sterile-packaging defect that will carry into 2027. Most significantly, management declined to reaffirm its 2027 targets of $1 billion in revenue and $180 million in EBITDA, both reaffirmed earlier this year. Instead, it framed the second half of 2026 as the base and guided to mid-30s incremental margins.

The balance sheet adds to the concern. Cash fell to $80 million from $161 million at year-end, partly because the remaining 2026 convertible notes were repaid in cash. Management put liquidity at about $135 million, down from roughly $204 million in the second quarter. Inventory climbed to $207 million from $169 million, and stockholders' equity turned to a small deficit. Management pointed to several positives:

• expanding the Valence indication to navigated TLIF;
• launching an EOS Insight Council with more than 70 key opinion leaders;
• hiring an EVP to lead data and informatics;
• tighter sales accountability and enforcement of distributor exclusivity on biologics.

The biologics actions address the core problem, but management offered no firm timeline, and the guidance assumes flat biologics.

The market setup heading into the report was more demanding than the fundamentals now justify. Shares closed at $11.45 the day before the release. That was up 16.0% from the open after the prior report, 33% above the September low of $8.60, 7.4% above the 200-day moving average, and just 1.3% below the inter-earnings high of $11.60. Investor sentiment remained negative but improved modestly, to -0.07 from -0.15. The Earnings Whispers trend readings were mostly positive going in, reflecting that run-up. Investors had grown more constructive just as management was preparing to lower the bar.

The bottom line is that Alphatec's procedural engine looks healthy, with record surgeon adds, 20% volume growth and steadily expanding EBITDA. However, revenue per case is eroding, growth is slowing, and three guidance cuts this year have weakened management's credibility on forecasting. Dropping the 2027 targets changes the investment setup. Bulls now need evidence that the biologics fix works and that margin gains hold without favorable mix. Until then, bears have legitimate ammunition.